 |
|
Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for HemodialysisA Randomized Controlled Trial
Laura M. Dember, MD;
Gerald J. Beck, PhD;
Michael Allon, MD;
James A. Delmez, MD;
Bradley S. Dixon, MD;
Arthur Greenberg, MD;
Jonathan Himmelfarb, MD;
Miguel A. Vazquez, MD;
Jennifer J. Gassman, PhD;
Tom Greene, PhD;
Milena K. Radeva, MS;
Gregory L. Braden, MD;
T. Alp Ikizler, MD;
Michael V. Rocco, MD, MSCE;
Ingemar J. Davidson, MD;
James S. Kaufman, MD;
Catherine M. Meyers, MD;
John W. Kusek, PhD;
Harold I. Feldman, MD, MSCE; for the Dialysis Access Consortium Study Group
JAMA. 2008;299(18):2164-2171.
Context The arteriovenous fistula is the preferred type of vascular access for hemodialysis because of lower thrombosis and infection rates and lower health care expenditures compared with synthetic grafts or central venous catheters. Early failure of fistulas due to thrombosis or inadequate maturation is a barrier to increasing the prevalence of fistulas among patients treated with hemodialysis. Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas.
Objective To determine whether clopidogrel reduces early failure of hemodialysis fistulas.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted at 9 US centers composed of academic and community nephrology practices in 2003-2007. Eight hundred seventy-seven participants with end-stage renal disease or advanced chronic kidney disease were followed up until 150 to 180 days after fistula creation or 30 days after initiation of dialysis, whichever occurred later.
Intervention Participants were randomly assigned to receive clopidogrel (300-mg loading dose followed by daily dose of 75 mg; n = 441) or placebo (n = 436) for 6 weeks starting within 1 day after fistula creation.
Main Outcome Measures The primary outcome was fistula thrombosis, determined by physical examination at 6 weeks. The secondary outcome was failure of the fistula to become suitable for dialysis. Suitability was defined as use of the fistula at a dialysis machine blood pump rate of 300 mL/min or more during 8 of 12 dialysis sessions.
Results Enrollment was stopped after 877 participants were randomized based on a stopping rule for intervention efficacy. Fistula thrombosis occurred in 53 (12.2%) participants assigned to clopidogrel compared with 84 (19.5%) participants assigned to placebo (relative risk, 0.63; 95% confidence interval, 0.46-0.97; P = .018). Failure to attain suitability for dialysis did not differ between the clopidogrel and placebo groups (61.8% vs 59.5%, respectively; relative risk, 1.05; 95% confidence interval, 0.94-1.17; P = .40).
Conclusion Clopidogrel reduces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proportion of fistulas that become suitable for dialysis.
Trial Registration clinicaltrials.gov Identifier: NCT00067119
Author Affiliations: Boston University (Drs Dember and Kaufman) and VA Boston Healthcare System (Dr Kaufman), Boston, Massachusetts; Cleveland Clinic Foundation, Cleveland, Ohio (Drs Beck and Gassman and Ms Radeva); University of Alabama at Birmingham (Dr Allon); Washington University in St Louis, St Louis, Missouri (Dr Delmez); University of Iowa, Iowa City (Dr Dixon); Duke University, Durham, North Carolina (Dr Greenberg); Maine Medical Center, Portland (Dr Himmelfarb); University of Texas-Southwestern, Dallas (Drs Vazquez and Davidson); University of Utah, Salt Lake City (Dr Greene); Baystate Medical Center, Springfield, Massachusetts (Dr Braden); Vanderbilt University, Nashville, Tennessee (Dr Ikizler); Wake Forest University, Winston-Salem, North Carolina (Dr Rocco); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (Drs Meyers and Kusek); and University of Pennsylvania, Philadelphia (Dr Feldman).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTERS
Effect of Clopidogrel on Arteriovenous Fistulas for Dialysis
Raghav Wusirika and Panduranga Rao
JAMA. 2008;300(14):1647.
EXTRACT
| FULL TEXT
Effect of Clopidogrel on Arteriovenous Fistulas for Dialysis
Dirk M. Hentschel and Arif Asif
JAMA. 2008;300(14):1647-1648.
EXTRACT
| FULL TEXT
Effect of Clopidogrel on Arteriovenous Fistulas for Dialysis
Costas Fourtounas and Jannis G. Vlachojannis
JAMA. 2008;300(14):1648.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Randomized Trials in Hemodialysis Patients: Time to Step Up to the Plate
Marcello Tonelli
JAMA. 2008;299(18):2205-2207.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency
Dixon et al.
NEJM 2009;360:2191-2201.
ABSTRACT
| FULL TEXT
Antiplatelet Therapy and Vascular-Access Patency
Lok
NEJM 2009;360:2240-2242.
FULL TEXT
Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients
Chan et al.
J. Am. Soc. Nephrol. 2009;20:872-881.
ABSTRACT
| FULL TEXT
Ethical and Legal Obligation to Avoid Long-Term Tunneled Catheter Access
Rehman et al.
CJASN 2009;4:456-460.
ABSTRACT
| FULL TEXT
Outcomes of Brachiocephalic Fistulas, Transposed Brachiobasilic Fistulas, and Upper Arm Grafts
Maya et al.
CJASN 2009;4:86-92.
ABSTRACT
| FULL TEXT
Effect of Clopidogrel on Arteriovenous Fistulas for Dialysis
Wusirika and Rao
JAMA 2008;300:1647-1647.
FULL TEXT
Effect of Clopidogrel on Arteriovenous Fistulas for Dialysis
Fourtounas and Vlachojannis
JAMA 2008;300:1648-1648.
FULL TEXT
Effect of Clopidogrel on Arteriovenous Fistulas for Dialysis
Hentschel and Asif
JAMA 2008;300:1647-1648.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;336:1156-1157.
FULL TEXT
Randomized Trials in Hemodialysis Patients: Time to Step Up to the Plate
Tonelli
JAMA 2008;299:2205-2207.
FULL TEXT
|
